RenalytixAI Receives California Commercial Lab Certification

September 25, 2020

RenalytixAI – a BioUtah member – announced on Tuesday that it has received a California Clinical Laboratory License from the California Department of Health for its clinical laboratory in Salt Lake City, Utah. This means that KidneyIntelX™ may now be used to report risk assessment of progressive decline in kidney function for patients in California with early stage diabetic kidney disease (DKD). With this certification, the company is now licensed to provide KidneyIntelX testing services for patients in 49 states.

“BioUtah is proud to have RenalytixAI here in Salt Lake City,” said Kelvyn Cullimore, president and CEO of BioUtah. “The company’s ability to deliver testing services to virtually every state in the nation is critical to patients with chronic kidney disease, and with CEO James McCullough at the helm, the company is helping to further expand Utah’s growing innovation hub.”

According to the American Society of Nephrology, California has more than five million patients with kidney diseases, 94,000 patients diagnosed with kidney failure and 68,000 patients on dialysis, one of the highest rates of CKD in the nation.

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.